Women with breast cancer who are treated with anti-estrogens have a lower lung cancer mortality rate than the general population, according to a study published online Jan. 24 in Cancer.
MONDAY, Jan. 24 (HealthDay News) -- Women with breast cancer who are treated with anti-estrogens have a lower lung cancer mortality rate than the general population, according to a study published online Jan. 24 in Cancer.
Christine Bouchardy, M.D., from the University of Geneva, and colleagues reviewed data from 6,655 women diagnosed with breast cancer between 1980 and 2003 who registered at the Geneva Cancer Registry. Of those diagnosed, 3,066 women were treated with anti-estrogens. The women were followed up until December 2007 to identify how many developed and died from lung cancer. Incidence and mortality rates were compared with those expected in the general population. The investigators found that 40 of the women developed lung cancer. Standardized incidence ratios for lung cancer were not significantly lower for breast cancer patients, regardless of whether they were receiving anti-estrogen therapy. However, lung cancer mortality was significantly lower for women taking anti-estrogens, compared to those without anti-estrogens (standardized mortality ratios, 0.13 versus 0.76). "Anti-estrogen treatment for breast cancer was associated with a reduced risk of death from lung cancer, providing new evidence on the role of estrogen in lung cancer progression," the authors write.
Abstract
Full Text (subscription or payment may be required)
Study links COVID-19 infection to higher low birthweight and preterm birth rates
March 24th 2025A new study found that pregnant women infected with COVID-19, especially in the third trimester or with severe symptoms, faced higher risks of preterm birth, low birthweight, and neonatal intensive care unit admission.
Read More
Low creatinine-to-cystatin C ratio linked to postmenopausal muscle loss
March 20th 2025A new study finds that postmenopausal women with a reduced creatinine-to-cystatin C ratio experience decreased muscle volume and slower walking speed, highlighting its role as a potential biomarker for muscle health.
Read More